The findings in mice may explain how addictive drugs hijack natural reward processing systems, creating the urge to use while throwing natural urges to eat and drink off-kilter.
Thomas Tuschl has devoted his career to making discoveries that bridge the gap between bench and business—and have resulted in entirely new classes of drugs.
Retinoic acid, the active state of Vitamin A, appears to regulate how stem cells enter and exit a transient state central to their role in wound repair.
uLIPSTIC, an updated method for directly observing physical interactions between cells, could allow scientists to one day map every possible cell interaction.
A novel platform allows researchers to directly target enzymes implicated in infectious diseases, several genetic disorders, and some cancers for the first time.
The end replication problem dictates that telomeres shrink unless telomerase intervenes. But the problem is actually twice as complicated, with telomerase providing only part of the solution.
The absence of a single immune cell receptor has been linked to both fewer defenses against mycobacterial infections, such as TB, and damaging buildup of sticky residue in the lungs.
A class of ineffective immune cells may be driving Alzheimer’s disease, a finding that could both explain why APOE4 gene increases the risk of the disease and why a new drug can impact it.
Luciano Marraffini’s research helped lay the groundwork for the newly FDA-approved CRISPR-based therapy for sickle cell anemia. He reflects on how we got here—and where the science is going next.
By focusing on the emergent features of cell collectives, instead of individual cells, scientists forge a new path for understanding how organs develop their architecture.
From plumbing the depths of wound repair to tackling how songbirds solve problems, here are some fascinating discoveries that came out of Rockefeller in 2023.
“I believe this is going to be a very fruitful find. Every time people have studied nutrient sensing, we’ve learned a lot about biology, and many drugs have been developed as a result.”
Why do our bodies not only fail to learn from prior dengue infection but also become more vulnerable to it as a result? New research pinpoints a subgroup of antibodies that may be to blame.
As with many cutting-edge therapies, we know more about the drug's effectiveness than we do about how it actually operates. A new study reveals a possible mechanism for its impact on patients.
Patients with a specific cocktail of COVID exposure had the highest level of antibodies against SARS-CoV-2 and its variants, which also provided a strong immunological shield for their babies.
With 40% of encephalitis cases now explained by an autoimmune deficiency, West Nile virus "is by far the best understood human infectious disease in the world. It’s stunning.”
They identified a brain signal that guides one type of decision-making—findings that could build a foundation for understanding how humans make educated and strategic decisions.
Fibrolamellar carcinoma not only hinders the body's ammonia consumption but also produces ammonia, a finding with sweeping implications for treating this cancer—and the study of ammonia metabolism.
The algorithm, dubbed SCRuB, can distinguish native bacteria and viruses from contaminants—a powerful tool for researchers working with the microbiome.
The labs of Ali Brivanlou and Charles M. Rice collaborated to refine a cell culture technology platform that grows genetically identical lung buds from human embryonic stem cells.
Research shed light on the process by which the γ-Tubulin Ring Complex stabilizes microtubules, which may inform the study of developmental diseases and cancers.
Damaged gums may release bacteria into the bloodstream that trigger arthritis flare-ups, potentially explaining why people with gum disease don't respond as well to arthritis treatments.
The tech, dubbed MesoLF, captures 10,500 neurons buried at once-inaccessible depths, firing from brain regions many millimeters apart, simultaneously—all with unprecedented resolution.
The relatively simple and low-cost procedure could empower laboratories in low-resource areas to generate nanobodies against SARS-CoV-2, as well as other viruses.
A trio of faulty genes fail to put the brakes on the immune system’s all-out assault on SARS-CoV-2, leading to the inflammatory overload characteristic of MIS-C.
A diverse immune response hinges on naive B cells mingling with high affinity ones in the late-stage germinal center. Whether that helps or hinders, however, depends on the virus.
